Breakthrough Chemistry, Inc.
Breakthrough Chemistry, Inc. Fundamental Analysis
Breakthrough Chemistry, Inc. (BKTH) shows moderate financial fundamentals with a PE ratio of 2.14, profit margin of 98.62%, and ROE of 1.49%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 79.5/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze BKTH's fundamental strength across five key dimensions:
Efficiency Score
ExcellentBKTH demonstrates superior asset utilization.
Valuation Score
ExcellentBKTH trades at attractive valuation levels.
Growth Score
WeakBKTH faces weak or negative growth trends.
Financial Health Score
ExcellentBKTH maintains a strong and stable balance sheet.
Profitability Score
ModerateBKTH maintains healthy but balanced margins.
Key Financial Metrics
Is BKTH Expensive or Cheap?
P/E Ratio
BKTH trades at 2.14 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, BKTH's PEG of 0.02 indicates potential undervaluation.
Price to Book
The market values Breakthrough Chemistry, Inc. at 1.59 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -39.81 times EBITDA. This is generally considered low.
How Well Does BKTH Make Money?
Net Profit Margin
For every $100 in sales, Breakthrough Chemistry, Inc. keeps $98.62 as profit after all expenses.
Operating Margin
Core operations generate -7.33 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.49 in profit for every $100 of shareholder equity.
ROA
Breakthrough Chemistry, Inc. generates $60.47 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Breakthrough Chemistry, Inc. generates limited operating cash flow of $-67.55K, signaling weaker underlying cash strength.
Free Cash Flow
Breakthrough Chemistry, Inc. generates weak or negative free cash flow of $-67.54K, restricting financial flexibility.
FCF Per Share
Each share generates $-0.01 in free cash annually.
FCF Yield
BKTH converts -2.31% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
2.14
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.02
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.59
vs 25 benchmark
P/S Ratio
Price to sales ratio
211.12
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.14
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.63
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
1.49
vs 25 benchmark
ROA
Return on assets percentage
0.60
vs 25 benchmark
ROCE
Return on capital employed
-0.06
vs 25 benchmark
How BKTH Stacks Against Its Sector Peers
| Metric | BKTH Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 2.14 | 26.30 | Better (Cheaper) |
| ROE | 149.34% | 1259.00% | Weak |
| Net Margin | 9861.81% | -33581.00% (disorted) | Strong |
| Debt/Equity | 0.14 | 0.74 | Strong (Low Leverage) |
| Current Ratio | 4.63 | 10.42 | Strong Liquidity |
| ROA | 60.47% | -1494138.00% (disorted) | Strong |
BKTH outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Breakthrough Chemistry, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Cyclical, Value, Infrastructure
EPS CAGR
N/A
Industry Style: Cyclical, Value, Infrastructure
FCF CAGR
N/A
Industry Style: Cyclical, Value, Infrastructure